129-46-4

• 常用中文名：舒拉明钠
• 常用英文名：Suramin sodium
• CAS号：129-46-4
• 分子式：C₅₁H₃₄N₆Na₆O₂₃S₆
• 分子量：1429.171
• 相关类别： 信号通路 G 蛋白偶联受体/G 蛋白 P2Y受体
• 发布时间：2018-08-03 16:41:18
• 更新时间：2024-01-04 17:44:19
• Suramin sodium salt是具有各种生物活性的多磺化萘脲。Suramin sodium salt是DNA topoisomerase II抑制剂，IC₅₀值为5 μM。

名称

• 中文名: 苏拉明钠
• 英文名: Suramin hexasodium salt
• 中文别名: 苏拉明; 8,8'-碳酰双亚氨-3,1-亚苯基碳酰亚氨-(4-甲基-3,1-亚苯基)碳酰亚氨双-1,3,5-萘三磺酸六钠; 舒拉明钠
• 英文别名: Hexasodium 8,8'-{carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]}di(1,3,5-naphthalenetrisulfonate); Suramin hexasodium salt; EINECS 204-949-3; Naphuride; Hexasodium 8-[(4-methyl-3-{[3-({[3-({2-methyl-5-[(4,6,8-trisulfonato-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl]carbamoyl}amino)benzoyl]amino}benzoyl)amino]naphthalene-1,3,5-trisulfonate; Suramin sodium salt; Hexasodium sym-Bis(m-aminobenzoyl-m-amino-p-methylbenzoyl-1-naphthylamino-4,6,8-trisulfonate) Carbamide; Suramin sodium; hexasodium 8-[(4-methyl-3-{[3-({[3-({2-methyl-5-[(4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl]phenyl}carbamoyl)phenyl]carbamoyl}amino)benzoyl]amino}benzoyl)amino]naphthalene-1,3,5-trisulfonate; hexasodium,8-[[4-methyl-3-[[3-[[3-[[2-methyl-5-[(4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]benzoyl]amino]naphthalene-1,3,5-trisulfonate; Suramin (Sodium Salt); Sodium suramin; suramine sodium; Suramine sodium salt; Suramin hexasodium; 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-, sodium salt (1:6); 309f; MFCD00210217

物化性质

• 分子式: C₅₁H₃₄N₆Na₆O₂₃S₆
• 分子量: 1429.171
• 精确质量: 1427.938599
• PSA: 551.01000
• LogP: 11.61040
• 外观性状: 白色
• 储存条件: 0-6°C
• 水溶解性: 可溶
• 计算化学:

  1.疏水参数计算参考值（XlogP）:无

  2.氢键供体数量:6

  3.氢键受体数量:23

  4.可旋转化学键数量:10

  5.互变异构体数量:155

  6.拓扑分子极性表面积551

  7.重原子数量:92

  8.表面电荷:0

  9.复杂度:2940

  10.同位素原子数量:0

  11.确定原子立构中心数量:0

  12.不确定原子立构中心数量:0

  13.确定化学键立构中心数量:0

  14.不确定化学键立构中心数量:0

  15.共价键单元数量:7

生物活性

• 描述: Suramin sodium salt是具有多种生物活性的多磺化萘基脲。 Suramin是DNA拓扑异构酶II抑制剂,IC50为5 μM。
• 相关类别:
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> P2Y受体
  研究领域 >> 癌症
• 靶点:

  IC50: 5 μM (DNA topoisomerase II)[3]

• 体外研究: 苏拉明抑制培养的HeLa细胞中的细胞增殖和DNA合成。通过40μM苏拉明完全消除SV40 DNA的复制。 DNA聚合酶α对较低浓度的苏拉明敏感(IC50 =8μM)比DNA聚合酶δ(IC50 =36μM)敏感,而DNA聚合酶β对药物相对不敏感(IC50为90μM)[1]。苏拉明是细菌RecA蛋白的DNA链交换和ATP酶活性的有效抑制剂。苏拉明抑制RecA催化的LexA阻遏蛋白水解切割。苏拉明这种抑制作用的机制涉及其拆解RecA-单链DNA细丝的能力[2]。苏拉明是核酶DNA拓扑异构酶II的有效抑制剂。苏拉明抑制纯化的酵母拓扑异构酶II,IC50约为5μM[3]。
• 体内研究: 与对照大鼠相比,苏拉明治疗在第21天显示出较低的肺动脉压,右心室肥大和远端血管肌肉化值。苏拉明治疗抑制PA-SMC增殖并减弱炎症反应和胶原沉积[4]。
• 激酶实验: ATP酶测定在10μL反应混合物中进行，所述反应混合物含有20mM Tris-HCl（pH 7.5），1mM DTT，8mM MgCl2,5μMM13环状ssDNA，来自指定细菌物种的2.5μMRecA和增加浓度的苏拉明。通过加入2mM [α-32P] ATP引发反应，在37℃温育30分钟并通过加入25mM EDTA终止反应[2]。
• 动物实验: 大鼠：为了评估苏拉明的潜在预防和疗效，在MCT注射后将大鼠随机分成4组。在预防策略中，治疗在第一天开始，并且一组每周两次静脉内接受10mg / kg苏拉明，持续3周，而第二组在相同时间点仅接受载体。为了评估苏拉明的潜在疗效，给予大鼠MCT并且不进行处理21天，然后将其随机分成两组，随后从第21天至第42天（包括苏拉明或载体）用苏拉明或载体治疗。从MCT注射的第21天到对应于治疗期的第42天评估苏拉明对存活的影响[4]。
• 参考文献:

  [1]. Jindal HK, et al. Suramin affects DNA synthesis in HeLa cells by inhibition of DNA polymerases. Cancer Res. 1990 Dec 15;50(24):7754-7.

  [2]. Nautiyal A, et al. Suramin is a potent and selective inhibitor of Mycobacterium tuberculosis RecA protein and the SOS response: RecA as a potential target for antibacterial drug discovery. J Antimicrob Chemother. 2014 Jul;69(7):1834-43.

  [3]. Bojanowski K, et al. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcomacells. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3025-9.

  [4]. Izikki M, et al. The beneficial effect of suramin on monocrotaline-induced pulmonary hypertension in rats. PLoS One. 2013 Oct 15;8(10):e77073.

MSDS

Name: Suramin.hexasodium salt Material Safety Data Sheet Synonym: CAS: 129-46-4 Section 1 - Chemical Product MSDS Name:Suramin.hexasodium salt Material Safety Data Sheet Synonym: Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS CAS# Chemical Name content EINECS# 129-46-4 Suramin.hexasodium salt 204-949-3 Hazard Symbols: None Listed. Risk Phrases: None Listed. Section 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Not available. Potential Health Effects Eye: May cause eye irritation. Skin: May cause skin irritation. Ingestion: May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. Inhalation: May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Chronic: Not available. Section 4 - FIRST AID MEASURES Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid. Skin: Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Ingestion: Get medical aid. Wash mouth out with water. Inhalation: Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Notes to Physician: Section 5 - FIRE FIGHTING MEASURES General Information: As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. Extinguishing Media: Use water spray, dry chemical, carbon dioxide, or chemical foam. Section 6 - ACCIDENTAL RELEASE MEASURES General Information: Use proper personal protective equipment as indicated in Section 8. Spills/Leaks: Vacuum or sweep up material and place into a suitable disposal container. Section 7 - HANDLING and STORAGE Handling: Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes. Storage: Store in a cool, dry place. Store in a tightly closed container. Keep refrigerated. (Store below 4C/39F.) Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION Engineering Controls: Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 129-46-4: Personal Protective Equipment Eyes: Not available. Skin: Wear appropriate protective gloves to prevent skin exposure. Clothing: Wear appropriate protective clothing to prevent skin exposure. Respirators: Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced. Section 9 - PHYSICAL AND CHEMICAL PROPERTIES Physical State: Powder Color: white Odor: Not available. pH: Not available. Vapor Pressure: Not available. Viscosity: Not available. Boiling Point: Not available. Freezing/Melting Point: Not available. Autoignition Temperature: Not available. Flash Point: Not available. Explosion Limits, lower: Not available. Explosion Limits, upper: Not available. Decomposition Temperature: Solubility in water: Soluble. Specific Gravity/Density: Molecular Formula: C51H34N6O23S6Na6 Molecular Weight: 1428.5632 Section 10 - STABILITY AND REACTIVITY Chemical Stability: Not available. Conditions to Avoid: Incompatible materials. Incompatibilities with Other Materials: Strong oxidizing agents. Hazardous Decomposition Products: Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide, sodium oxide. Hazardous Polymerization: Will not occur. Section 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 129-46-4: QM7000000 LD50/LC50: Not available. Carcinogenicity: Suramin.hexasodium salt - Not listed by ACGIH, IARC, or NTP. Other: See actual entry in RTECS for complete information. Section 12 - ECOLOGICAL INFORMATION Section 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations. Section 14 - TRANSPORT INFORMATION IATA No information available. IMO No information available. RID/ADR No information available. Section 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives Hazard Symbols: Not available. Risk Phrases: Safety Phrases: S 24/25 Avoid contact with skin and eyes. WGK (Water Danger/Protection) CAS# 129-46-4: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 129-46-4 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 129-46-4 is not listed on the TSCA inventory. It is for research and development use only. SECTION 16 - ADDITIONAL INFORMATION N/A

毒性和生态

毒理学数据: 1、急性毒性：小鼠经腹腔LD5O：750mg/kg 小鼠经静脉LD5O：620mg/kg 2、其他多剂量毒性：大鼠经腹腔TDLO：252mg/m^3/7W-I 小鼠经腹腔TDLO：1750mg/m^3/7D-I CHEMICAL IDENTIFICATION RTECS NUMBER : QM7000000 CHEMICAL NAME : 1,3,5-Naphthylenetrisulfonic acid, 8,8'-(ureylenebis(m-phenylenecarbonylimino(4-methyl- m-phenylene)carbonylimino))di-, hexasodium salt CAS REGISTRY NUMBER : 129-46-4 LAST UPDATED : 199512 DATA ITEMS CITED : 4 MOLECULAR FORMULA : C51-H34-N6-O23-S6.6Na MOLECULAR WEIGHT : 1429.21 WISWESSER LINE NOTATION : L66J BSWQ DSWQ GSWQ JMVR D1 CMVR CMVMR CVMR B1 EVM- JL66J BSWQ DSWQ GSWQ &-NA- 6 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 750 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : BBRCA9 Biochemical and Biophysical Research Communications. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 136,64,1986 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 620 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : 85KYAH "Merck Index; an Encyclopedia of Chemicals, Drugs, and Biologicals", 11th ed., Rahway, NJ 07065, Merck & Co., Inc. 1989 Volume(issue)/page/year: 11,1423,1989 ** OTHER MULTIPLE DOSE TOXICITY DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 252 mg/kg/7W-I TOXIC EFFECTS : Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Kidney, Ureter, Bladder - other changes REFERENCE : IVIVE4 In Vivo. (POB 51359, Kiffisia, GR-145 10, Greece) V.1- 1987- Volume(issue)/page/year: 6,617,1992 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 1750 mg/kg/7D-I TOXIC EFFECTS : Related to Chronic Data - death REFERENCE : BBRCA9 Biochemical and Biophysical Research Communications. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 136,64,1986

安全

• 个人防护装备: Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
• 危害码 (欧洲): Xn
• 风险声明 (欧洲): R22:Harmful if swallowed. R36/38:Irritating to eyes and skin .
• 安全声明 (欧洲): 22-24/25
• 危险品运输编码: NONH for all modes of transport
• WGK德国: 3
• RTECS号: QM7000000

合成路线

10397-30-5 ~% 129-46-4

文献：Journal of Medicinal Chemistry, , vol. 48, # 22 p. 7040 - 7048

上下游产品

上游产品  1
10397-30-5
下游产品  0